Lifecore Biomedical Inc expected to post a loss of 9 cents a share - Earnings Preview

• Lifecore Biomedical Inc LFCR is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending May 31 2025

• The Chaska Minnesota-based company is expected to report a 6.7% decrease in revenue to $35.363 million from $37.89 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Lifecore Biomedical Inc is for a loss of 9 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Lifecore Biomedical Inc is $10.00, about 25.9% above its last closing price of $7.41

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated August 5 at 20:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)